譜尼測試(300887.SZ):子公司擬斥1.5億元建設山東總部大廈暨研發檢測中心大樓
格隆匯 3 月 12日丨譜尼測試(300887.SZ)公佈,基於公司長遠發展業務規劃,為拓展公司的服務網絡,公司全資子公司譜尼測試集團山東有限公司(“山東譜尼”)擬使用自籌資金共計1.5億元用於建設山東總部大廈暨研發檢測中心大樓,公司已於近日取得該建設用地的《國有建設用地使用權出讓合同》、《建設用地規劃許可證》,該土地用途為工業用地。
因此公司未來將緊緊依託國家國民經濟和社會發展第十四個五年規劃和二〇三五年遠景目標等發展戰略,謀篇佈局,不斷擴大實驗室建設。設立山東總部大廈,將極大地促進譜尼測試品牌在山東區域的提升及市場佔有率與影響力,更好的為客户提供更加便利、快捷的檢測技術服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.